Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Sees Unusually High Call Option Buying

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) was the recipient of some unusual options trading on Monday. Stock traders bought 7,885 call options on the stock. This represents an increase of 69% compared to the average daily volume of 4,661 call options.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Wall Street Zen raised Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, September 27th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Eyepoint Pharmaceuticals in a report on Monday, August 17th. Weiss Ratings raised shares of Eyepoint Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 1st. Citigroup lowered their target price on shares of Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating for the company in a report on Tuesday, August 18th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, August 18th. Four research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $25.70.

Institutional Trading of Eyepoint Pharmaceuticals

Institutional investors have recently modified their holdings of the company. KBC Group NV purchased a new position in Eyepoint Pharmaceuticals in the first quarter valued at approximately $29,000. Integrated Wealth Concepts LLC acquired a new position in Eyepoint Pharmaceuticals during the second quarter valued at approximately $72,000. Pictet Asset Management Holding SA acquired a new stake in shares of Eyepoint Pharmaceuticals in the first quarter worth $141,000. Engineers Gate Manager LP purchased a new stake in Eyepoint Pharmaceuticals during the 2nd quarter worth $161,000. Finally, Janney Montgomery Scott LLC increased its holdings in Eyepoint Pharmaceuticals by 14.8% in the 1st quarter. Janney Montgomery Scott LLC now owns 30,315 shares of the company’s stock valued at $391,000 after purchasing an additional 3,900 shares in the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Stock Performance

Eyepoint Pharmaceuticals stock traded down $2.52 during midday trading on Monday, reaching $0.47. The stock had a trading volume of 78,354,800 shares, compared to its average volume of 2,423,693. The stock’s 50-day simple moving average is $5.02 and its 200 day simple moving average is $10.39. Eyepoint Pharmaceuticals has a twelve month low of $0.43 and a twelve month high of $19.11. The stock has a market capitalization of $40.69 million, a PE ratio of -0.12 and a beta of 1.67.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.08). The firm had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.45 million. Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. Equities analysts predict that Eyepoint Pharmaceuticals will post -3.51 earnings per share for the current fiscal year.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.